¥ 4/ 6

PATENT/Docket No. PC9868D Serial No. 10/825,406

Page 3

RCE in response to 06/14/05 Advisory Action following 04/01/05 Final OA

## Amendment to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

## **Listing of Claims**

Claims 1-27. (Cancelled)

28. (New) A compound of the formula

or the pharmaceutically acceptable salt thereof;

wherein a is 1;

V is CHR<sup>10</sup> wherein R<sup>10</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

T is nitrogen or CH;

X is nitrogen;

Y and Z are each independently nitrogen or  $CR^{12}$ , wherein  $R^{12}$  is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano,  $(C_1-C_6)$ alkoxy or  $(C_1-C_6)$ alkyl, provided that at least one of T, Y, and Z is nitrogen;

 $R^1$  is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or  $(C_1-C_6)$ alkyl;  $R^2$ ,  $R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$  are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano,  $(C_1-C_6)$ alkoxy and  $(C_1-C_6)$ alkyl;

R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

 $R^5$  is hydrogen,  $(C_1-C_6)$ alkoxy, trifluoromethyl, cyano,  $(C_1-C_6)$ alkyl or  $R^{13}$ CO- wherein  $R^{13}$  is amino,  $(C_1-C_6)$ alkylamino,  $((C_1-C_6)$ alkyl)<sub>2</sub>amino,  $(C_1-C_6)$ alkyl,  $(C_6-C_{10})$ aryl.

- 29. (New) A compound according to claim 28, wherein Y and Z are each CR<sup>12</sup> wherein R<sup>12</sup> is hydrogen or fluoro.
- 30. (New) A compound according to claim 28, wherein R<sup>2</sup> is hydrogen, fluoro or chloro.
- 31. (New) A compound according to claim 28, wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen.
- 32. (New) A compound according to claim 28, wherein R<sup>7</sup> is fluoro or chloro.

FORM PTORSP Rev. 5/1/03

PATENT/Docket No. PC9868D

Serial No. 10/825,406

Page 4

RCE in response to 06/14/05 Advisory Action following 04/01/05 Final OA

- (New) A compound according to claim 28, wherein R<sup>9</sup> is fluoro, chloro, bromo or 33. alkoxy.
- 34. (New) A compound according to claim 28, wherein X is nitrogen; Y and Z are each CR<sup>12</sup> wherein R<sup>12</sup> is hydrogen or fluoro; R<sup>2</sup> is hydrogen fluoro or chloro; R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>7</sup> is fluoro or chloro; and R<sup>7</sup> is fluoro, chloro, bromo or alkoxy.
- 35. (New) A compound according to claim 28, wherein said compound is selected from the group consisting of:
  - 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
  - 2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-ylmethyl]-5-fluoro-1H-indole;
  - 5-Fluoro-2-(4-[5'-fluoro]pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;
  - 2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole;

5-30-05; 10:30AM; PHARMACIA

- 5-Fluoro-2-(4-pyridin-2-yl-piperazin-1-ylmethyl)-1H-indole; and
- 5-Fluoro-2-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-1H-indole.
- 36. (Currently amended) A method for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to claim 28, or a pharmaceutically acceptable salt thereof, that iseffective in treating such disorder wherein the disorder is psychotic disorders selected from affective psychosis, schizophrenia, and schizoaffective disorders. 37-43. (Cancelled).